Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Forbion European Acquisition Corp.FRBNU · Entity 108709 | Director | December 09, 2021 | December 09, 2021 |
| Replimune Group, Inc.REPL · Entity 4707 | Director | August 20, 2026 | August 24, 2026 |
| enGene Therapeutics Inc.ENGN · Entity 6638 | Director | June 16, 2026 | June 17, 2026 |
| uniQure N.V.QURE · Entity 4162 | Director | March 02, 2021 | March 04, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Forbion European Acquisition Corp.
Report date December 09, 2021 · Filed December 09, 2021
This filing explicitly reported no securities owned.
Replimune Group, Inc.
Report date August 20, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,362,414 |
Reported balance
After 2026-08-20 transaction · row 1
1 source rowRow 1 · 2026-08-20 · Gift · Disposed 50,000 · Balance 1,362,414 F1: Represents a bona fide gift of 50,000 shares from the reporting person to a donor-advised fund. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a bona fide gift of 50,000 shares from the reporting person to a donor-advised fund.
enGene Therapeutics Inc.
Report date June 16, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2036-06-16 | Direct | 31,000 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 31,000 · Balance 31,000 F1: This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders.
uniQure N.V.
Report date March 02, 2021 · Filed March 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 9,946 |
Reported balance
After 2021-03-02 transaction · row 1
1 source rowRow 1 · 2021-03-02 · Sale · Disposed 504 · Balance 9,946 F1: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.76 to $37.61. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.76 to $37.61. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2026 Filed Aug 24, 2026 23:48 UTC | Replimune Group, Inc. REPL · Entity 4707 | GiftCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-100437 · tm2623932-1_4seq1.xml · nonDerivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,362,414 F1 · kind: Represents a bona fide gift of 50,000 shares from the reporting person to a donor-advised fund. Read SEC document |
| June 16, 2026 Filed Jun 17, 2026 21:44 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 31,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0000929638-26-002263 · form4.xml · derivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Shares · 31,000 shares Expires 2036-06-16 F1 · derivative.exercise_date: This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:16 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 17,657 | $5.08 | $89,697.56 |
DisclosureSEC source: 0001104659-26-064522 · tm2615137-3_4seq1.xml · nonDerivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,412,414 F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $5.02 to $5.08 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range. Read SEC document |
| April 01, 2026 Filed Apr 8, 2026 01:10 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $7.61 | $0.00 |
DisclosureSEC source: 0001104659-26-040577 · tm2611350-14_4seq1.xml · derivative · entry 2 Astley-Sparke Philip · CIK 0001376491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2036-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2027, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2026 Filed Apr 8, 2026 01:10 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-040577 · tm2611350-14_4seq1.xml · nonDerivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,430,071 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2027 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2030, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:15 UTC | Replimune Group, Inc. REPL · Entity 4707 | GiftCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-018159 · tm266938-1_4seq1.xml · nonDerivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,380,071 Read SEC document |
| July 08, 2025 Filed Jul 10, 2025 20:07 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $3.83 | $0.00 |
DisclosureSEC source: 0000929638-25-002558 · form4.xml · derivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Shares · 45,000 shares Expires 2035-07-08 F1 · derivative.exercise_date: This option vests at 1/3 on each of the first, second and third anniversaries of Mr. Astley-Sparke's date of appointment to the Board, which was July 8, 2025. Read SEC document |
| May 20, 2025 Filed May 23, 2025 01:47 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 32,279 | $8.06 | $260,168.74 |
DisclosureSEC source: 0001104659-25-052147 · tm2515608-7_4seq1.xml · nonDerivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,405,071 F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $8.05 to $8.80 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range. Read SEC document |
| August 30, 2024 Filed Aug 31, 2024 00:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | GiftCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-095834 · tm2423182-1_4seq1.xml · nonDerivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,437,350 Read SEC document |
| May 16, 2024 Filed May 21, 2024 00:04 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 37,928 | $6.47 | $245,394.16 |
DisclosureSEC source: 0001104659-24-063561 · tm2414961-4_4seq1.xml · nonDerivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,487,350 F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $6.46 to $6.55 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range. Read SEC document |
| May 16, 2023 Filed May 19, 2023 00:30 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 17,902 | $18.05 | $323,131.10 |
DisclosureSEC source: 0001104659-23-062370 · tm2316199-2_4seq1.xml · nonDerivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,525,278 F1 · shares: Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreement under which the RSU was granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.05 to $18.23. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 213,150 | $0.00 Strike: $17.66 | $0.00 |
DisclosureSEC source: 0001104659-23-041717 · tm2311410-1_4seq1.xml · derivative · entry 2 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,150 Underlying: Common Stock · 213,150 shares Expires 2033-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2024, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 142,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-041717 · tm2311410-1_4seq1.xml · nonDerivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,543,180 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2024 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2027, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| May 16, 2022 Filed May 18, 2022 23:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 9,632 | $14.59 | $140,530.88 |
DisclosureSEC source: 0001104659-22-062605 · tm2215879d2_4seq.xml · nonDerivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,401,080 F1 · shares: Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreement under which the RSU was granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.57 to $14.59. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:18 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $18.26 | $0.00 |
DisclosureSEC source: 0001104659-22-042773 · tm2211665-1_4seq1.xml · derivative · entry 2 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2032-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2023, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:18 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042773 · tm2211665-1_4seq1.xml · nonDerivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,410,712 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2023 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2026, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:17 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 128,125 | $0.00 Strike: $31.58 | $0.00 |
DisclosureSEC source: 0001104659-21-046728 · tm2112099-10_4seq1.xml · derivative · entry 2 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,125 Underlying: Common Stock · 128,125 shares Expires 2031-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2022, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:17 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 85,415 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-046728 · tm2112099-10_4seq1.xml · nonDerivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,340,712 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2022 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2025, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 19:26 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 504 | $37.60 | $18,950.40 |
DisclosureSEC source: 0000904454-21-000297 · edgar.xml · nonDerivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,946 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.76 to $37.61. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:26 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 4,107 | $0.00 Strike: $37.00 | $0.00 |
DisclosureSEC source: 0000904454-21-000263 · edgar.xml · derivative · entry 2 Astley-Sparke Philip · CIK 0001376491 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,107 Underlying: Ordinary Shares · 4,107 shares Expires 2031-02-25 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:26 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 2,382 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-21-000263 · edgar.xml · nonDerivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,450 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 02:53 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 7,632 | $42.40 | $323,596.80 |
DisclosureSEC source: 0001104659-21-005571 · tm213368-6_4seq1.xml · nonDerivative · entry 8 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,255,297 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 6, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.04 to $42.85. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F9 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 1,255,297 shares of the Issuer's common stock. The reporting person also holds options to acquire 647,571 shares of the Issuer's common stock, 230,907 of which are exercisable as of the date hereof. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 02:53 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 800 | $43.15 | $34,520.00 |
DisclosureSEC source: 0001104659-21-005571 · tm213368-6_4seq1.xml · nonDerivative · entry 7 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,262,929 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 6, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.88 to $43.86. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 02:53 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 9,409 | $43.02 | $404,775.18 |
DisclosureSEC source: 0001104659-21-005571 · tm213368-6_4seq1.xml · nonDerivative · entry 6 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,263,729 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 6, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.56 to $43.25. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 02:53 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 6,059 | $43.71 | $264,838.89 |
DisclosureSEC source: 0001104659-21-005571 · tm213368-6_4seq1.xml · nonDerivative · entry 5 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,273,138 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 6, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.26 to $44.25. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 02:53 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 1,100 | $44.95 | $49,445.00 |
DisclosureSEC source: 0001104659-21-005571 · tm213368-6_4seq1.xml · nonDerivative · entry 4 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,279,197 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 6, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.55 to $45.26. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 14, 2021 Filed Jan 20, 2021 02:53 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 100 | $43.06 | $4,306.00 |
DisclosureSEC source: 0001104659-21-005571 · tm213368-6_4seq1.xml · nonDerivative · entry 3 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,280,297 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 6, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 14, 2021 Filed Jan 20, 2021 02:53 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 7,448 | $43.61 | $324,807.28 |
DisclosureSEC source: 0001104659-21-005571 · tm213368-6_4seq1.xml · nonDerivative · entry 2 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,280,397 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 6, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.14 to $44.07. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 14, 2021 Filed Jan 20, 2021 02:53 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 17,452 | $44.78 | $781,500.56 |
DisclosureSEC source: 0001104659-21-005571 · tm213368-6_4seq1.xml · nonDerivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,287,845 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 6, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.09 to $45.08. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 10, 2020 Filed Dec 12, 2020 02:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 3,863 | $42.39 | $163,752.57 |
DisclosureSEC source: 0001104659-20-134933 · tm2038101-4_4seq1.xml · nonDerivative · entry 8 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,305,297 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 6, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.45 to $42.26. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F10 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 1,305,297 shares of the Issuer's common stock. The reporting person also holds options to acquire 647,571 shares of the Issuer's common stock, 220,022 of which are exercisable as of the date hereof. Read SEC document |
| December 10, 2020 Filed Dec 12, 2020 02:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 16,051 | $42.99 | $690,032.49 |
DisclosureSEC source: 0001104659-20-134933 · tm2038101-4_4seq1.xml · nonDerivative · entry 7 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,309,160 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 6, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.45 to $42.46. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 10, 2020 Filed Dec 12, 2020 02:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 5,086 | $43.72 | $222,359.92 |
DisclosureSEC source: 0001104659-20-134933 · tm2038101-4_4seq1.xml · nonDerivative · entry 6 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,325,211 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 6, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.45 to $43.46. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 09, 2020 Filed Dec 12, 2020 02:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 800 | $42.03 | $33,624.00 |
DisclosureSEC source: 0001104659-20-134933 · tm2038101-4_4seq1.xml · nonDerivative · entry 5 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,330,297 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 6, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.29 to $41.78. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 09, 2020 Filed Dec 12, 2020 02:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 11,116 | $43.09 | $478,988.44 |
DisclosureSEC source: 0001104659-20-134933 · tm2038101-4_4seq1.xml · nonDerivative · entry 4 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,331,097 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 6, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.40 to $42.48. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 09, 2020 Filed Dec 12, 2020 02:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 6,459 | $43.88 | $283,420.92 |
DisclosureSEC source: 0001104659-20-134933 · tm2038101-4_4seq1.xml · nonDerivative · entry 3 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,342,213 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 6, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.40 to $43.42. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 09, 2020 Filed Dec 12, 2020 02:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 6,025 | $44.85 | $270,221.25 |
DisclosureSEC source: 0001104659-20-134933 · tm2038101-4_4seq1.xml · nonDerivative · entry 2 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,348,672 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 6, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.40 to $44.41. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 09, 2020 Filed Dec 12, 2020 02:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 600 | $45.79 | $27,474.00 |
DisclosureSEC source: 0001104659-20-134933 · tm2038101-4_4seq1.xml · nonDerivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,354,697 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 6, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.47 to $45.56. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 20:30 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 265,000 | $0.00 Strike: $9.78 | $0.00 |
DisclosureSEC source: 0001104659-20-042496 · a4.xml · derivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,000 Underlying: Common Stock · 265,000 shares Expires 2030-04-01 F1 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2021, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 20:43 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 3,620 | $0.00 Strike: $51.81 | $0.00 |
DisclosureSEC source: 0000904454-20-000255 · edgar.xml · derivative · entry 2 Astley-Sparke Philip · CIK 0001376491 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,620 Underlying: Ordinary Shares · 3,620 shares Expires 2030-02-27 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 20:43 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 2,063 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000255 · edgar.xml · nonDerivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,068 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| January 30, 2020 Filed Jan 31, 2020 02:39 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 807 | $59.23 | $47,798.61 |
DisclosureSEC source: 0000904454-20-000124 · edgar.xml · nonDerivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,005 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. Read SEC document |
| November 06, 2019 Filed Nov 9, 2019 02:16 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 14,500 | $17.00 | $246,500.00 |
DisclosureSEC source: 0001104659-19-061831 · a4.xml · nonDerivative · entry 2 Astley-Sparke Philip · CIK 0001376491 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,355,297 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 1,355,297 shares of the Issuer's common stock. The reporting person also holds options to acquire 382,571 shares of the Issuer's common stock, 94,103 of which are exercisable as of the date hereof. Read SEC document |
| November 06, 2019 Filed Nov 9, 2019 02:16 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 14,500 | $17.02 | $246,790.00 |
DisclosureSEC source: 0001104659-19-061831 · a4.xml · nonDerivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,369,797 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| November 04, 2019 Filed Nov 7, 2019 00:38 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 14,500 | $17.00 | $246,500.00 |
DisclosureSEC source: 0001104659-19-060675 · a4.xml · nonDerivative · entry 2 Astley-Sparke Philip · CIK 0001376491 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,384,297 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 1,384,297 shares of the Issuer's common stock. The reporting person also holds options to acquire 382,571 shares of the Issuer's common stock, 94,103 of which are exercisable as of the date hereof. Read SEC document |
| November 04, 2019 Filed Nov 7, 2019 00:38 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 14,500 | $17.05 | $247,254.00 |
DisclosureSEC source: 0001104659-19-060675 · a4.xml · nonDerivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,398,797 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| October 31, 2019 Filed Nov 4, 2019 21:16 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 14,500 | $17.00 | $246,500.00 |
DisclosureSEC source: 0001104659-19-059509 · a4.xml · nonDerivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,413,297 F1 · kind: The sale reported on this Form 4 was made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Following the sale reported on this Form 4, the reporting person continues to beneficially own 1,413,297 shares of the Issuer's common stock. The reporting person also holds options to acquire 382,571 shares of the Issuer's common stock, 94,103 of which are exercisable as of the date hereof. Read SEC document |
| September 23, 2019 Filed Sep 25, 2019 20:31 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 14,500 | $17.05 | $247,225.00 |
DisclosureSEC source: 0001104659-19-051355 · a4.xml · nonDerivative · entry 1 Astley-Sparke Philip · CIK 0001376491 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,427,797 F1 · kind: The sale reported on this Form 4 was made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Following the sale reported on this Form 4, the reporting person continues to beneficially own 1,427,797 shares of the Issuer's common stock. The reporting person also holds options to acquire 382,571 shares of the Issuer's common stock, 87,457 of which are exercisable as of the date hereof. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 16:21 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,200 | $61.15 | $73,380.00 |
DisclosureSEC source: 0000904454-19-000590 · edgar.xml · nonDerivative · entry 4 Astley-Sparke Philip · CIK 0001376491 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,812 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.01 to $61.33. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 16:21 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 2,994 | $60.65 | $181,586.10 |
DisclosureSEC source: 0000904454-19-000590 · edgar.xml · nonDerivative · entry 3 Astley-Sparke Philip · CIK 0001376491 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,012 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.94. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 16:21 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,400 | $59.30 | $83,020.00 |
DisclosureSEC source: 0000904454-19-000590 · edgar.xml · nonDerivative · entry 2 Astley-Sparke Philip · CIK 0001376491 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,006 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.97 to $59.69. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.